GA-ENTERSEKT
11.1.2023 12:27:43 CET | Business Wire | Press release
Entersekt, a global leader in customer and payment authentication solutions for financial fraud prevention, today announced the appointment of Jon Roskill, former Acumatica CEO and Microsoft executive, to its board of directors as part of its continued expansion within North America. In late 2021, Entersekt received significant funding from Accel-KKR, a technology-focused private equity firm, to hire key leadership, launch new branding, and accelerate the expansion within this region.
Jon Roskill joins Entersekt board of directors
A former Corporate Vice President at Microsoft, and CEO of Acumatica, Mr. Roskill brings decades of executive and advisory experience to the Entersekt board as the company continues to introduce advanced customer and payment authentication solutions into the North American market as part of its global expansion. He currently serves as a Senior Advisor with EQT Partners after spending eight years with Acumatica, a cloud ERP provider.
“Jon joins our board of directors at a critical time. Entersekt is at an inflection point in our growth and expansion, particularly in North America,” said Schalk Nolte, CEO of Entersekt. “His vast experience in global go-to-market strategies will bring tremendous value to the company.”
“Entersekt has a tremendous opportunity ahead of it, and I’m excited to be joining at such a pivotal time in its growth” added Roskill. “With proven, patented technologies, excellent leadership, a strong, global customer base and solid financial foundation, I look forward to being a part of Entersekt’s next phase as it establishes itself as a global leader in financial fraud prevention.”
Expansion of the leadership team to drive bullish growth strategy
In addition, Entersekt has also hired new additions to the management team to support and accelerate the speed to market of Context Aware™ Authentication in North America. Key hires include Matt Loos as Chief Revenue Officer, Pradheep Sampath as Chief Product Officer and Frank Moreno as Chief Marketing Officer.
The new team brings with them the following strong leadership experience in the financial services industry:
- Loos joins Entersekt with over 20 years of leadership experience at companies like Fifth Third Bank and Mastercard.
- Sampath holds a 25-year track record in scaling SaaS, mobile and API-based products for companies like ID.me and GXS.
- Moreno’s experience includes senior marketing leadership roles spanning over 20 years with companies such as Bottomline and Datawatch.
New strategic partnerships as global growth enablers
Many new integrations and partnerships with strategic technology providers are currently underway. Most recently, Entersekt’s biometric authentication technology was integrated into Q2’s Digital Banking Platform. Q2 is a leading provider of digital transformation solutions for banking and lending. By supporting pre-integration, these partnerships enable banks to quickly and easily deploy Entersekt’s state-of-the-art authentication technology.
Targeting the demand for enhanced security
A recent Forrester Survey of 300 North American fraud prevention decision-makers, reported that all respondents had experienced authentication fraud in the past year. “The investment from Accel-KKR will support the significant market opportunity and demand for the cloud-first, global authentication solutions that Entersekt is known for. We have a strong leadership team in place that will play a critical role in accelerating our business vision to expand and scale into this territory”, concludes Nolte.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230111005470/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release
If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids
Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release
Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use
DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release
-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
